6,945 Shares in Becton, Dickinson and Company $BDX Purchased by United Services Automobile Association

Key Points

• United Services Automobile Association acquired 6,945 shares of Becton, Dickinson and Company (BDX) during the first quarter, representing a total investment of approximately $1,580,000.
• Analysts have recently downgraded BDX's target price, with Barclays lowering it from $261.00 to $241.00, while Piper Sandler raised its price objective from $185.00 to $200.00.
• Becton, Dickinson and Company reported earnings of $3.68 EPS, beating analyst expectations, with a revenue increase of 10.4% year-over-year.

United Services Automobile Association acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,945 shares of the medical instruments supplier's stock, valued at approximately $1,580,000.

Several other hedge funds have also bought and sold shares of BDX. GQG Partners LLC bought a new stake in Becton, Dickinson and Company during the first quarter worth about $689,833,000. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares in the last quarter. Nuveen LLC bought a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $211,097,000. GAMMA Investing LLC lifted its stake in shares of Becton, Dickinson and Company by 29,654.0% in the first quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock worth $170,523,000 after buying an additional 741,943 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after buying an additional 667,957 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Barclays dropped their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler reissued a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $211.44.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 863 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the sale, the director directly owned 23,143 shares of the company's stock, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Up 0.5%

Shares of BDX stock opened at $192.18 on Monday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a market cap of $55.08 billion, a P/E ratio of 34.56, a P/E/G ratio of 1.44 and a beta of 0.27. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a 50 day simple moving average of $185.08 and a two-hundred day simple moving average of $192.60.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. During the same period in the prior year, the company earned $3.50 earnings per share. The firm's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.